Intravenous trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonia
Related Experiment Video
Updated: Oct 23, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Abstract:
Twenty-nine immunocompromised patients were treated with intravenous trimethoprim-sulfamethoxazole for possible Pneumocystis carinii pneumonia. The diagnosis was established in 15 severely hypoxemic patients with lymphoreticular malignancy or cardiac transplants by open lung biopsy or transthoracic needle aspirate. In 13 (87 percent) of the 15, the response to therapy was rapid. They became afebrile in a mean of 2.1 days, showed improved arterial blood oxygenation in 4.7 days and improvements on the chest roentgenogram in 4.3 days. Eight (53 percent) of the 15 survived and were clinically cured. Five other patients with documented P. carinii infection improved clinically but subsequently died of other causes. Postmortem examination in these showed no P. carinii cysts. Two patients with P. carinii pneumonia died soon after therapy was started and had P. carinii cysts in lung tissue at autopsy. The combined clinical and microbiologic response of 87 percent equals or exceeds that of other reported treatment regimens. Intravenous trimethoprim-sulfamethoxazole may, therefore, be the most ideal therapy for severely ill adults with P. carinii pneumonia. Second lung biopsies in 12 patients on therapy showed that P. carinii cysts were rarely found after several days of treatment. This suggests that lung tissue may be falsely negative for P. carinii cysts in persons treated empirically but who later undergo lung biopsy.
Insights
Intravenous trimethoprim-sulfamethoxazole effectively treated Pneumocystis pneumonia in immunocompromised adults. This therapy showed rapid clinical improvement and survival rates comparable or superior to other treatments.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Pneumocystis pneumonia (PCP) is a severe opportunistic infection, particularly in immunocompromised individuals.
- Effective treatment is crucial for improving outcomes in patients with PCP.
Purpose of the Study:
- To evaluate the efficacy of intravenous trimethoprim-sulfamethoxazole for treating Pneumocystis pneumonia in severely ill, immunocompromised patients.
- To compare the treatment response and survival rates with existing therapeutic regimens.
Main Methods:
- Retrospective analysis of 29 immunocompromised patients treated with intravenous trimethoprim-sulfamethoxazole for suspected PCP.
- Diagnosis confirmed in 15 patients via open lung biopsy or transthoracic needle aspirate.
- Clinical response, including fever resolution, oxygenation improvement, and chest X-ray changes, was monitored.
Main Results:
- 87% of patients with confirmed PCP showed a rapid clinical and microbiological response to therapy.
- Mean time to becoming afebrile was 2.1 days, improved oxygenation 4.7 days, and improved chest X-rays 4.3 days.
- Survival rate was 53% (8 of 15 patients), with others dying from unrelated causes; 2 patients died early in treatment with persistent P. carinii cysts.
Conclusions:
- Intravenous trimethoprim-sulfamethoxazole demonstrates high efficacy and rapid response in severely ill adults with Pneumocystis pneumonia.
- This regimen may be the most ideal therapy for severe PCP, offering outcomes equal to or exceeding other treatments.
- Empirical treatment may lead to false-negative lung biopsies for P. carinii cysts due to rapid cyst clearance.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:27Cryptococcal Meningitis